Mingu Kang

Lunit Inc

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 21 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Table S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Chang Gon Kim,Min Hee Hong,Dahee Kim,Brian Hyohyoung Lee,Hyunwook Kim,Chan-Young Ock,Geoffrey Kelly,Yoon Ji Bang,Gamin Kim,Jung Eun Lee,Chaeyeon Kim,Se-Heon Kim,Hyun Jun Hong,Young Min Park,Nam Suk Sim,Heejung Park,Jin Woo Park,Chang Geol Lee,Kyung Hwan Kim,Goeun Park,Inkyung Jung,Dawoon Han,Jong Hoon Kim,Junha Cha,Insuk Lee,Mingu Kang,Heon Song,Chiyoon Oum,Seulki Kim,Sukjun Kim,Yoojoo Lim,Seunghee Kim-Schulze,Miriam Merad,Sun Och Yoon,Hyun Je Kim,Yoon Woo Koh,Hye Ryun Kim

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S3 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0WOSBibtex

Comparison of Tumor Microenvironments Between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment

Dong Hyun Kim,Jong Seok Ahn,Mingu Kang,Gahee Park,Yoojoo Lim, Soohyun Hwang,Chan-Young Ock,Jiwon Koh,Eun-Jae Chung,Seong-Keun Kwon,Yoon Kyung Jeon,Kyeong Cheon Jung,Soon-Hyun Ahn,Bhumsuk Keam

Cells（2024）

Cited0Views0WOSBibtex

Supplementary Figure S6 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S4 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S8 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S5 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab Plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

crossref（2024）

Cited0Views0Bibtex

Artificial Intelligence-Powered Analysis of Tumor-Stroma Ratio and Fibroblast Density As Prognostic Indicators in Colorectal Cancer

Minsun Jung,Jun Yong Kim,Mingu Kang,Jinhee Lee,Sanghoon Song,Taebum Lee,Wonkyung Jung,Soo Ick Cho

CANCER RESEARCHno. 6 (2024)

Cited0Views0Bibtex

Author Statistics

#Papers: 21

#Citation: 46

H-Index: 2

G-Index: 2

Sociability: 4

Diversity: 1

Activity: 2

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn